GlassScriptPhysician profile
Mark K Piker
NPI 1396898086
$1,703.74
in general payments reported to CMS, 2019-2025
15 companies · $84.60 in 2025
The $84.60 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $321 · 2021: $276 · 2022: $183 · 2023: $66.36 · 2024: $38.68 · 2025: $84.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $189.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $343.27 | 2019-2021 | |
| Abbvie INC. | $297.21 | 2021-2025 | |
| Amgen INC. | $185.42 | 2020-2021 | |
| Allergan, INC. | $159.76 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $149.87 | 2019-2022 | |
| Emd Serono, INC. | $123.83 | 2019-2021 | |
| Genzyme Corporation | $79.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $77.36 | 2020 | |
| Merz North America, INC. | $66.49 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $64.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $63.11 | 2022 | |
| Zyla Life Sciences, INC. | $42.28 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.02 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.93 | 2021 | |
| Celgene Corporation | $13.70 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Piker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.